Rafferty Asset Management LLC Sells 9,057 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Rafferty Asset Management LLC lessened its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 2.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 331,412 shares of the biopharmaceutical company's stock after selling 9,057 shares during the period. Rafferty Asset Management LLC owned 0.21% of TG Therapeutics worth $9,976,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in TGTX. Quadrant Capital Group LLC lifted its position in shares of TG Therapeutics by 137.1% during the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock valued at $51,000 after buying an additional 975 shares during the last quarter. Blue Trust Inc. lifted its position in shares of TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 371 shares during the last quarter. Smartleaf Asset Management LLC lifted its position in shares of TG Therapeutics by 512.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock valued at $60,000 after buying an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp raised its stake in shares of TG Therapeutics by 460.7% during the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 1,737 shares during the period. Finally, Synergy Asset Management LLC bought a new stake in shares of TG Therapeutics during the 4th quarter valued at $75,000. Hedge funds and other institutional investors own 58.58% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on TGTX. HC Wainwright reiterated a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $40.80.

TG Therapeutics Price Performance

Shares of NASDAQ:TGTX traded up $0.49 on Tuesday, hitting $35.47. The company's stock had a trading volume of 1,492,004 shares, compared to its average volume of 2,991,470. The company has a 50-day simple moving average of $38.54 and a 200 day simple moving average of $34.08. TG Therapeutics, Inc. has a 1 year low of $15.16 and a 1 year high of $46.48. The company has a market capitalization of $5.63 billion, a PE ratio of -354.66 and a beta of 2.21. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $120.86 million during the quarter, compared to analysts' expectations of $117.07 million. During the same period in the previous year, the business earned ($0.07) EPS. The business's revenue was up 90.4% on a year-over-year basis. Sell-side analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.